908 Devices [MASS] vs Abbott Laboratories [ABT] Detailed Stock Comparison
908 Devices
NASDAQ
Loading...
Abbott Laboratories
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: 908 Devices wins in 9 metrics, Abbott Laboratories wins in 9 metrics, with 0 ties. Both stocks appear equally matched on key metrics.
View Metrics Details
Vital Metrics Comparison
| Metric | 908 Devices | Abbott Laboratories | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -2.95 | 16.48 | 908 Devices |
| Price-to-Book Ratio | 1.53 | 4.52 | 908 Devices |
| Debt-to-Equity Ratio | 2.98 | 26.50 | 908 Devices |
| PEG Ratio | -5.89 | 0.45 | 908 Devices |
| EV/EBITDA | -2.62 | 20.56 | 908 Devices |
| Profit Margin (TTM) | -28.13% | 32.43% | Abbott Laboratories |
| Operating Margin (TTM) | -64.20% | 19.73% | Abbott Laboratories |
| EBITDA Margin (TTM) | N/A | 19.73% | N/A |
| Return on Equity | -53.40% | 30.93% | Abbott Laboratories |
| Return on Assets (TTM) | -15.39% | 6.62% | Abbott Laboratories |
| Free Cash Flow (TTM) | $-30.85M | $6.35B | Abbott Laboratories |
| Dividend Yield | N/A | 1.28% | N/A |
| 1-Year Return | 58.48% | 15.98% | 908 Devices |
| Price-to-Sales Ratio (TTM) | 3.47 | 5.30 | 908 Devices |
| Enterprise Value | $115.71M | $235.48B | Abbott Laboratories |
| EV/Revenue Ratio | 1.77 | 5.46 | 908 Devices |
| Gross Profit Margin (TTM) | 48.89% | 56.44% | Abbott Laboratories |
| Revenue per Share (TTM) | $2 | $25 | Abbott Laboratories |
| Earnings per Share (Diluted) | $-2.36 | $7.97 | Abbott Laboratories |
| Beta (Stock Volatility) | 0.37 | 0.71 | 908 Devices |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
908 Devices vs Abbott Laboratories Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| 908 Devices | -0.63% | 3.99% | -14.60% | 5.03% | 179.46% | 185.84% |
| Abbott Laboratories | -0.07% | -0.48% | 3.97% | -0.49% | -4.81% | 15.81% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| 908 Devices | 58.48% | -64.31% | -87.61% | -87.61% | -87.61% | -87.61% |
| Abbott Laboratories | 15.98% | 28.17% | 26.12% | 205.02% | 439.51% | 510.17% |
Performance & Financial Health Analysis: 908 Devices vs Abbott Laboratories
| Metric | MASS | ABT |
|---|---|---|
| Market Information | ||
| Market Cap | $227.34M | $228.57B |
| Market Cap Category | Micro cap | Mega cap |
| 10 Day Avg. Volume | 223,570 | 4,793,458 |
| 90 Day Avg. Volume | 275,233 | 6,842,669 |
| Last Close | $6.26 | $131.37 |
| 52 Week Range | $1.81 - $8.06 | $110.86 - $141.23 |
| % from 52W High | -22.33% | -6.98% |
| All-Time High | $79.60 (Feb 08, 2021) | $142.60 (Dec 27, 2021) |
| % from All-Time High | -92.14% | -7.88% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.14% | 0.07% |
| Quarterly Earnings Growth | -0.07% | 0.37% |
| Financial Health | ||
| Profit Margin (TTM) | -0.28% | 0.32% |
| Operating Margin (TTM) | -0.64% | 0.20% |
| Return on Equity (TTM) | -0.53% | 0.31% |
| Debt to Equity (MRQ) | 2.98 | 26.50 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $4.13 | $29.05 |
| Cash per Share (MRQ) | $3.29 | $4.18 |
| Operating Cash Flow (TTM) | $-28,653,000 | $9.04B |
| Levered Free Cash Flow (TTM) | $-2,116,750 | $5.92B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 1.28% |
| Last 12-Month Dividend | N/A | $1.69 |
Valuation & Enterprise Metrics Analysis: 908 Devices vs Abbott Laboratories
| Metric | MASS | ABT |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -2.95 | 16.48 |
| Forward P/E | -5.89 | 25.45 |
| PEG Ratio | -5.89 | 0.45 |
| Price to Sales (TTM) | 3.47 | 5.30 |
| Price to Book (MRQ) | 1.53 | 4.52 |
| Market Capitalization | ||
| Market Capitalization | $227.34M | $228.57B |
| Enterprise Value | $115.71M | $235.48B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.77 | 5.46 |
| Enterprise to EBITDA | -2.62 | 20.56 |
| Risk & Other Metrics | ||
| Beta | 0.37 | 0.71 |
| Book Value per Share (MRQ) | $4.13 | $29.05 |
Financial Statements Comparison: 908 Devices vs Abbott Laboratories
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | MASS | ABT |
|---|---|---|
| Revenue/Sales | $11.78M | $10.36B |
| Cost of Goods Sold | $6.24M | $4.47B |
| Gross Profit | $5.54M | $5.89B |
| Research & Development | $3.83M | $716.00M |
| Operating Income (EBIT) | $-8.53M | $1.69B |
| EBITDA | $-4.74M | $2.66B |
| Pre-Tax Income | $-9.84M | $1.78B |
| Income Tax | N/A | $453.00M |
| Net Income (Profit) | $43.60M | $1.33B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | MASS | ABT |
|---|---|---|
| Cash & Equivalents | $79.16M | $6.53B |
| Total Current Assets | $149.00M | $23.15B |
| Total Current Liabilities | $19.56M | $13.00B |
| Long-Term Debt | $2.71M | $12.74B |
| Total Shareholders Equity | $159.42M | $49.06B |
| Retained Earnings | $-199.20M | $47.72B |
| Property, Plant & Equipment | $5.08M | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | MASS | ABT |
|---|---|---|
| Operating Cash Flow | $47.77M | $1.42B |
| Capital Expenditures | $-159,000 | $-484.00M |
| Free Cash Flow | $-15.18M | $933.00M |
| Debt Repayment | N/A | $-1.00B |
| Common Stock Repurchase | N/A | $-280.00M |
Short Interest & Institutional Ownership Analysis
| Metric | MASS | ABT |
|---|---|---|
| Shares Short | 2.01M | 17.11M |
| Short Ratio | 6.70 | 2.18 |
| Short % of Float | 0.11% | 0.01% |
| Average Daily Volume (10 Day) | 223,570 | 4,793,458 |
| Average Daily Volume (90 Day) | 275,233 | 6,842,669 |
| Shares Outstanding | 35.10M | 1.73B |
| Float Shares | 22.13M | 1.73B |
| % Held by Insiders | 0.08% | 0.01% |
| % Held by Institutions | 0.83% | 0.81% |
Dividend Analysis & Yield Comparison: 908 Devices vs Abbott Laboratories
| Metric | MASS | ABT |
|---|---|---|
| Last 12-Month Dividend | N/A | $1.69 |
| Last 12-Month Dividend Yield | N/A | 1.28% |
| 3-Year Avg Annual Dividend | N/A | $1.92 |
| 3-Year Avg Dividend Yield | N/A | 0.49% |
| 3-Year Total Dividends | N/A | $5.77 |
| Ex-Dividend Date | N/A | Jan 15, 2025 |